Edition:
United States

Cempra Inc (CEMP.O)

CEMP.O on Nasdaq

4.05USD
24 Feb 2017
Change (% chg)

$0.90 (+28.57%)
Prev Close
$3.15
Open
$4.12
Day's High
$4.75
Day's Low
$4.00
Volume
21,606,882
Avg. Vol
2,751,573
52-wk High
$26.95
52-wk Low
$2.55

Select another date:

Fri, Feb 24 2017

Cempra's bacterial skin infection drug clears study, shares surge

Cempra Inc said on Friday that its experimental oral drug to treat acute bacterial skin infections cleared a late-stage study, bringing the antibiotic developer one step closer to getting its first drug to market.

UPDATE 2-Cempra's bacterial skin infection drug clears study, shares surge

* Cempra shares rise 38 pct, set for best day ever (Adds details, analyst comment)

BRIEF-Cempra’s fusidic acid achieves primary endpoint in phase 3 study of Absssi

* Cempra’s fusidic acid achieves primary endpoint in phase 3 study of Absssi

REFILE-Cempra's bacterial skin infection drug succeeds in key study

Feb 24 Cempra Inc said on Friday that its experimental drug to treat acute bacterial skin infections met the main goal of a late-stage study, sending the company's shares surging 41 percent in premarket trading.

FDA rejects Cempra's antibiotic for pneumonia, shares sink

Cempra Inc said on Thursday the U.S. Food and Drug Administration had rejected its antibiotic for community-acquired bacterial pneumonia (CABP), citing inadequate data on the drug's impact on the liver and manufacturing issues.

U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

The effectiveness of Cempra Inc's antibiotic to treat community-acquired pneumonia outweighs the risk of liver injury, an advisory panel to the U.S. Food and Drug Administration narrowly concluded on Friday.

UPDATE 2-U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

Nov 4 The effectiveness of Cempra Inc's antibiotic to treat community-acquired pneumonia outweighs the risk of liver injury, an advisory panel to the U.S. Food and Drug Administration narrowly concluded on Friday.

U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

Nov 4 The effectiveness of Cempra Inc's experimental antibiotic to treat community acquired pneumonia outweighs the risk of liver injury, an advisory panel to the U.S. Food and Drug Administration concluded on Friday.

BRIEF-Cempra stock trading halted today FDA advisory committee to discuss Solithromycin

* Cempra stock trading halted today; FDA advisory committee to discuss solithromycin

FDA highlights liver safety issues in Cempra drug review

Cempra Inc's experimental drug to treat community-acquired pneumonia, the kind recently suffered by presidential candidate Hillary Clinton, causes a potentially concerning rise in liver enzymes, according to a preliminary review by the U.S. Food and Drug Administration.

Select another date:

More From Around the Web